PepGen Announces Pricing of $100 Million Public Offering | PepGen
Summary
PepGen announced the pricing of an underwritten public offering of 31.25 million shares at $3.20 per share. The company expects to raise about $100 million in gross proceeds before fees and expenses. PepGen plans to use the funds for ongoing research and clinical development, including the FREEDOM-DM1 and FREEDOM2-DM1 trials, along with working capital and general corporate purposes. The offering is expected to close around September 26, 2025, subject to customary conditions.
Funding
Amount
$100.0M
Total raised
Date
September 24, 2025
Announcement date
Investors
Stifel, Nicolaus & Company, Leerink Swann & Company
Lead investors
Company
pepgen.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected